SCHEMBL365343

SCHEMBL365343

CS(=O)(=O)NC(=O)c1ccc(OCc2cccc(F)c2F)cc1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAOB P27338 3/20 0.52
PARP15 Q460N3 1/20 0.49
PARP14 Q460N5 1/20 0.49
PARP10 Q53GL7 1/20 0.49
SCN9A Q15858 4/20 0.48
SCN5A Q14524 1/20 0.48
SCN3A Q9NY46 1/20 0.47
SENP7 Q9BQF6 2/20 0.44
NPC1 O15118 1/20 0.44
CASP3 P42574 1/20 0.44
RAB9A P51151 1/20 0.44
SMN1; SMN2 Q16637 1/20 0.44
TAAR1 Q96RJ0 1/20 0.44
ALKBH1 Q13686 1/20 0.43
PTGER4 P35408 1/20 0.43
SENP8 Q96LD8 1/20 0.42
SENP6 Q9GZR1 1/20 0.42
GRM2 Q14416 1/20 0.42
CXCL8 P10145 1/20 0.42
BCL2L1 Q07817 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL365141 0.90 MAOB (0.65) MAOBPARP15PARP14PARP10SCN9A
SCHEMBL365285 0.81 SCN9A (0.52) SCN9ASCN5ASCN3ARAB9ASMN1; SMN2
SCHEMBL14890492 0.81 MAOA (0.52) MAOBSCN9ASCN5ASCN3APTGER4
SCHEMBL14890039 0.81 MAOB (0.67) MAOBSCN9ASCN5APTGER4MMP1
SCHEMBL14890368 0.81 SCN9A (0.54) MAOBSCN9ASCN5ASCN3APTGER4
SCHEMBL364245 0.80 MAOA (0.65) MAOBSCN9ASCN5ASCN3ANPC1
SCHEMBL14889855 0.80 SCN9A (0.53) MAOBSCN9ASCN5ASCN3APTGER4
SCHEMBL365767 0.80 MAOB (0.67) MAOBSCN9ASCN3AMCL1MMP1
SCHEMBL365920 0.79 RORC (0.62) PARP14PARP10SCN9ASCN3ANPC1
SCHEMBL14890410 0.79 SCN9A (0.57) MAOBSCN9ASCN5ASCN3APTGER4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9096500-B2 Acyl sulfonamide compounds PFIZER LIMITED (GB) 2015-08-04 US disclosed
EP-2593428-B1 N-SULFONYLBENZAMIDES AS INHIBITORS OF VOLTAGE-GATED SODIUM CHANNELS PFIZER LTD (GB) 2014-11-19 EP disclosed
EP-2593428-A2 N-SULFONYLBENZAMIDES AS INHIBITORS OF VOLTAGE-GATED SODIUM CHANNELS Pfizer Limited (GB) 2013-05-22 EP disclosed
US-20130109701-A1 Chemical Compounds PFIZER LIMITED (GB) 2013-05-02 US disclosed
WO-2012007868-A2 CHEMICAL COMPOUNDS PFIZER LIMITED (GB) 2012-01-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130109701-A1 Chemical Compounds SCN1A, SCN1B, SCN7A MAOB 3660/4885PARP15 1143/4885PARP14 2045/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.